991   **SUPPLEMENTAL FIGURES**

992

993   Supplemental Figure 1

994

995

996

997

998   Supplemental Figure 1 legend:

999   To validate our primary results, we performed a second analysis using a paired

1000   approach in which each PASC participant was matched to a control participant for

1001   genotype, sex, and age ±5 years. Because no control participant fit these criteria for one

1002   PASC participant, they were left out of the paired validation analysis. Genotype and sex

1003   were directly matched; neither age nor cerebellum SUV differed between cases and

1004   controls (p>0.05). Example slices through sagittal (x=3), coronal (y=-7), and axial (z=8)

1005   sections of the 11 PASC > 11 control group-level unpaired validation comparison,

1006   showing the pattern of increased [^{11}C]PBR28 signal. Color bar: threshold min. Z score of

1007   2 and max. 3.54. (Figure is shown in neurological convention)

1008

1009   Supplemental Figure 2

1010

1011   Supplemental Figure 2 legend:

1012   Correlation matrix showing relationships among cytokines from a 15 cytokine multiplex

1013   (Millipore HCYTA-60K Luminex magnetic bead panel performed by Eve Technologies,

1014   Calgary Canada), from the 11 PASC participants that provided platelet-poor plasma

1015   samples immediately before PET neuroimaging.

1016   Analytes included: GM-CSF, IFNγ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-

1017   12(p40), IL-12(p70), IL-13, MCP-1, TNFα. * = p<0.05; ** = p<0.01; *** = p<0.001

1018 Supplemental Figure 3

1019

PASC participant	1	2	3	4	5	6	7	8	9	10	11	12
Headache	9	8	0	2	0	7	10	6	0	9	6	2
Unrested	10	8	4	6	1	0	10	9	7	5	10	7
Muscle } Pain Joint }	10	3	0	2	6	6	10	6	5	1	3	2
Short Term Memory	7	6	6	4	4	0	10	0	2	6	2	7
Processing Information	9	6	6	6	4	0	10	3	3	6	3	5

1020

1021

1022 Supplemental Figure 3 legend:

1023 Each of the 12 PASC participants rated symptoms from the ICC "Neurological

1024 impairments" cluster on a 1-10 severity scale and marked their onset. For Pain, the ICC

1025 asked about "Significant pain" but the history questionnaire distinguished between

1026 muscle and joint pain.

1027 Light green = Not reported as a problem

1028 Orange = "This was a problem for me before COVID"

1029 Pink = "This is a problem for me since I had COVID"

1030 Red = "This is a serious problem for me since I had COVID"

1031

1032

1033

1034

1035

1036

1037   Supplemental Table 1

Affective items	PASC mean (SD)	Control mean (SD)
Sadness	0.58 (0.67)	0.095 (0.48)
Pessimism	0.67 (0.49)	0.024 (0.15)
Sense of failure	0.00 (0.00)	0.024 (0.15)
Dissatisfaction	0.67 (0.65)	0.095 (0.30)
Guilt	0.17 (0.39)	0.023 (0.15)
Feeling of punishment	0.00 (0.00)	0.048 (0.22)
Disappointment in self	0.17 (0.39)	0.024 (0.16)
Self-criticism	0.58 (0.51)	0.048 (0.22)
Suicidal thoughts	0.083 (0.29)	0.00 (0.00)
Crying episodes	0.42 (0.90)	0.048 (0.22)
Irritability	0.42 (0.51)	0.24 (0.69)
Social withdrawal	0.50 (0.52)	0.048 (0.22)
Indecisiveness	1.00 (0.74)	0.00 (0.00)
Average affective items	**0.40 (0.23)**	**0.055 (0.10)**
Somatic Items		
Change of body image	0.42 (0.51)	0.024 (0.15)
Ability to work	1.17 (0.94)	0.073 (0.26)
Sleep difficulties	0.75 (0.45)	0.17 (0.44)
Fatigability	1.42 (0.79)	0.073 (0.26)

Loss of Appetite	0.58 (0.79)	0.024 (0.15)
Weight loss	0.083 (0.29)	0.048 (0.22)
Health anxiety	1.08 (0.67)	0.00 (0.00)
Loss of libido	0.83 (1.03)	0.071 (0.26)
Average somatic items	**0.79 (0.39)**	**0.060 (0.13)**
Total score averages	**11.58 (1.74)**	**1.14 (5.58)**

1038

1039   Supplemental Table 1 legend:

1040   PASC and Control participant means for BDI items within the affective and somatic

1041   subscales of the BDI. A mixed-model ANOVA revealed a significant interaction driven by

1042   high somatic item means within the PASC group.

1043

1044

1045